^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    epirubicin

    Company:
    Generic mfg.
    Drug class:
    Topoisomerase II inhibitor
    Related drugs:
    1d
    DSN1 drives breast cancer progression via cell cycle regulation: diagnostic and therapeutic implications. (PubMed, Front Oncol)
    Drug sensitivity analysis showed that the DSN1 high expression group was resistant to drugs such as Epirubicin, Cyclophosphamide, Ribociclib, and Palbociclib, but relatively sensitive to tamoxifen and lapatinib. DSN1 contributes to breast cancer progression by modulating cell cycle pathways, making it a potential diagnostic and therapeutic target with clinical applicability.
    Journal
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • CCNB1 (Cyclin B1)
    |
    Ibrance (palbociclib) • lapatinib • tamoxifen • cyclophosphamide • Kisqali (ribociclib) • epirubicin
    3d
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) (clinicaltrials.gov)
    P2, N=111, Recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HR positive
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Herceptin (trastuzumab) • paclitaxel • Loqtorzi (toripalimab-tpzi) • cyclophosphamide • epirubicin • trastuzumab rezetecan (SHR-A1811)
    4d
    Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Sun Yat-sen University
    New P2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Loqtorzi (toripalimab-tpzi) • epirubicin
    5d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    5d
    SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC (clinicaltrials.gov)
    P3, N=318, Recruiting, West China Hospital | Not yet recruiting --> Recruiting | N=120 --> 318
    Enrollment open • Enrollment change • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    5d
    Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    MammaPrint®
    |
    paclitaxel • doxorubicin hydrochloride • Irene (pyrotinib) • cyclophosphamide • epirubicin
    6d
    A Phase II Clinical Study of Sequential Iparomlimab and Tuvonralimab Combined with Chemotherapy Following Local Radiotherapy in Breast Cancer Patients with Poor Response to Neoadjuvant Chemotherapy (ChiCTR2600117206)
    P=N/A, N=30, Not yet recruiting, The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    carboplatin • albumin-bound paclitaxel • epirubicin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    6d
    Exploratory Study of Transarterial Chemoembolization (TACE) Combined with Eparlitozoviril Antibody and Lenvatinib for Intermediate-to-Advanced Hepatocellular Carcinoma (ChiCTR2600117109)
    P=N/A, N=30, Recruiting, The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University
    New trial
    |
    Lenvima (lenvatinib) • epirubicin • Qibeian (iparomlimab/tuvonralimab)
    6d
    A Multicenter Study of Babao Dan to Reduce Inflammation After Treatment for Early-Stage Bladder Cancer (ChiCTR2500113268)
    P=N/A, N=82, Not yet recruiting, Renji Hospital, Shanghai Jiao Tong University School of Medicine; Renji Hospital, Shanghai Jiao Tong University School of Medicine
    New trial
    |
    epirubicin
    6d
    A Multicenter Randomized Controlled Clinical Trial of Neoadjuvant Endocrine Therapy versus Chemotherapy in Patients with HR+/HER2- Early-Stage Breast Cancer (ChiCTR2500111780)
    P4, N=148, Not yet recruiting, Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    paclitaxel • cyclophosphamide • Kisqali (ribociclib) • letrozole • epirubicin • goserelin acetate
    6d
    Efficacy and Safety of Epirubicin Plus Anlotinib Versus Epirubicin Plus Ifosfamide as Standard First-Line Regimens in Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma: A Randomized, Non-Comparative Study (ChiCTR2500113449)
    P2, N=58, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P2 trial
    |
    Focus V (anlotinib) • ifosfamide • epirubicin
    9d
    Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)